drugset
drugset / Trial / NCT05995275

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

NCT05995275 ↗

Phase 1/2 Completed 351 enrolled ModernaTX, Inc.
RandomizedSequentialQuadruple-blindPrevention

Summary

The goal of this study is to assess the safety, tolerability and immunogenicity of mRNA-1769 in healthy adult participants.

Timeline

Start
2023-08-15
Primary completion
2025-07-08
Completion
2025-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-1769 Unknown — Intramuscular

Indications

smallpox